ClinicalTrials.gg

Program

BIIB144

A development code.

Its studies are led by Biogen.

Furthest: phase 1, since Jun 18, 20261 company-led study, 1 open or runningNext primary completion: Jun 19, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogen11 open or runningphase 1since Jun 18, 2026Jun 18, 2026Jun 19, 2028phase 1 · NCT07662148

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 18, 2026First study: phase 1 study in Healthy VolunteerFirst studyNCT07662148 · 48 planned · United States

Ahead

  1. Jun 19, 2028Primary completion: phase 1 study in Healthy VolunteerNCT07662148

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07662148Healthy Volunteer · United States1RecruitingJun 19, 202848

How it is read

Names in the registry

  • “BIIB144”, 1 entry

Codes read as this program: BIIB144.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.